,24 Furthermore, spesolimab (anti-IL-36 receptor blocker), a monoclonal antibody approved for the treatment of generalized pustular psoriasis, did not reach the phase-2a randomized placebo-controlled trial primary endpoint in PPP either.26 The gene discussed is IL1RL2; the disease is generalized pustular psoriasis.